Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis

被引:15
作者
Geiss, HC [1 ]
Parhofer, KG [1 ]
Schwandt, P [1 ]
机构
[1] Univ Munich, Klinikum Grosshadern, Dept Internal Med 2, D-8000 Munich, Germany
关键词
atorvastatin; hypercholesterolaemia; LDL apheresis; simvastatin;
D O I
10.1046/j.1365-2796.1999.00401.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. Atorvastatin is a new potent HMG-CoA reductase inhibitor. We evaluated whether patients with coronary heart disease and severe hypercholesterolaemia showing insufficient LDL (low-density lipoprotein) cholesterol reduction despite combined therapy with simvastatin and regular LDL apheresis will benefit from atorvastatin therapy. Setting. Tertiary care centre, university hospital. Methods. In 21 patients treated by LDL apheresis, concomitant simvastatin therapy (40 mg day(-1)) was replaced by atorvastatin (40 mg day(-1)) and increased to 60 and 80 mg day(-1) (each for 3 months) if no side-effects were reported and NCEP treatment goals were not reached. Results. In 20 of 21 patients (95%), atorvastatin resulted in significant reduction of LDL cholesterol compared with simvastatin (by 10%, additional 8% and additional 1%, with 40, 60 and 80 mg day(-1) respectively). In four patients, NCEP treatment goals were reached (in three by atorvastatin alone, and in one by atorvastatin and apheresis). Patients with little reduction in LDL cholesterol to 40 mg day(-1) atorvastatin benefited most by increasing the dose to 60 mg day(-1) (additional 13% reduction),whilst those responding to atorvastatin 40 mg day(-1) benefited less (additional 1.9% reduction). During atorvastatin therapy, significantly less plasma had to be treated during apheresis resulting in shorter apheresis time. Eight patients (38%) reported side-effects, resulting in discontinuation of atorvastatin in three (14%) and dose reduction in five patients (24%), whilst no elevation of biochemical markers was observed. Conclusion. Concomitant atorvastatin therapy is superior to simvastatin therapy in patients with severe hypercholesterolaemia treated with regular LDL apheresis, but is associated with a high rate of subjective side-effects.
引用
收藏
页码:47 / 55
页数:9
相关论文
共 22 条
[1]   Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia [J].
BakkerArkema, RG ;
Davidson, MH ;
Goldstein, RJ ;
Davignon, J ;
Isaacsohn, JL ;
Weiss, SR ;
Keilson, LM ;
Brown, WV ;
Miller, VT ;
Shurzinske, LJ ;
Black, DM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (02) :128-133
[2]  
BakkerArkema RG, 1997, ATHEROSCLEROSIS, V134, P119
[3]   A brief review paper of the efficacy and safety of atorvastatin in early clinical trials [J].
BakkerArkema, RG ;
Best, J ;
Fayyad, R ;
Heinonen, TM ;
Marais, AD ;
Nawrocki, JW ;
Black, DM .
ATHEROSCLEROSIS, 1997, 131 (01) :17-23
[4]   Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia [J].
Bertolini, S ;
Bon, GB ;
Campbell, LM ;
Farnier, M ;
Langan, J ;
Mahla, G ;
Pauciullo, P ;
Sirtori, C ;
Egros, F ;
Fayyad, R ;
Nawrocki, JW .
ATHEROSCLEROSIS, 1997, 130 (1-2) :191-197
[5]  
Blache D, 1997, ATHEROSCLEROSIS, V134, P120
[6]   Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs [J].
Burnett, JR ;
Wilcox, LJ ;
Telford, DE ;
Kleinstiver, SJ ;
Barrett, PHR ;
Newton, RS ;
Huff, MW .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) :2589-2600
[7]  
Campeau L, 1997, NEW ENGL J MED, V336, P153
[8]   A multicenter, double-blind, one-year study comparing safety and efficacy of Atorvastatin versus Simvastatin in patients with hypercholesterolemia [J].
Dart, A ;
Jerums, G ;
Nicholson, G ;
dEmden, M ;
HamiltonCraig, I ;
Tallis, G ;
Best, J ;
West, M ;
Sullivan, D ;
Bracs, P ;
Black, D .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (01) :39-44
[9]   Comparison of one-year efficacy and safety of Atorvastatin versus Lovastatin in primary hypercholesterolemia [J].
Davidson, M ;
McKenney, J ;
Stein, E ;
Schrott, H ;
BakkerArkema, R ;
Fayyad, R ;
Black, D .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (11) :1475-1481
[10]   New lipid lowering drugs and new effects of old drugs [J].
Dujovne, CA .
CURRENT OPINION IN LIPIDOLOGY, 1997, 8 (06) :362-368